New synthetic chitosan Schiff bases bearing pyranoquinolinone or benzonaphthyridine and their silver nanoparticles derivatives with potential activity as antioxidant and molecular docking study for EGFR inhibitors
Authors:
Open Access
- 18 September 2024
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 14 (41) , 29919-29933
Abstract
In this study, two new carboxaldehydes 3, and 4 were synthesized by Vilsmeier–Haack formylation of 6-butyl-benzo[h][1,6]naphthyridine-2,5-dione 2 and 6-butyl-pyrano[3,2-c]quinolinone 1, respectively. Structures of newly synthesized compounds were achieved by IR, 1H NMR, 13C NMR, mass techniques, and elemental analyses. The two synthesized carboxaldehydes 3 and 4 were used as precursors for the synthesis of two new chitosan-based Schiff bases, CS1 and CS2. The new chitosan Schiff bases were grafted on silver nanoparticles, providing CS1/Ag and CS2/Ag structures. However, CS1 and CS2 and their silver nanoparticles were characterized by FT-IR, XRD, SEM-EDX, XRF, TEM, TGA, and DSC. The target compounds CS1, CS2, CS1/Ag, and CS2/Ag were assessed as radical scavengers against 1,1-diphenyl-2-picrylhydrazyl radicals (DPPH%). The results showed that CS1 and CS2 had a better ability to scavenge DPPH radical than its unmodified chitosan. CS1/Ag and CS2/Ag, combining the unique properties of silver and Schiff bases, displayed excellent antioxidant activity (IC50, 59.13, and 32.54 μg mL−1, respectively). In addition, the previous compounds were tested in vitro for inhibition of epidermal growth factor receptor (EGFR) tyrosine kinase using the EGFR kinase assay kit (Cat. #40321). In particular, compound CS1/Ag displayed potent inhibitory activity towards EGFR with IC50 20.45 μg mL−1 compared to reference drug sorafenib (IC50 = 0.76 μg mL−1). The bioactivity of new chitosan Schiff bases was studied by molecular docking to see how they bind with the EGFR receptor. The results implied that CS1 has a higher binding energy than CS2 and CS regarding EGFR kinase, which agreed with the results obtained from the experimental EGFR inhibition assay.Keywords
Funding Information
- Ain Shams University
This publication has 85 references indexed in Scilit:
- The epidermal growth factor receptor in malignant gliomas: pathogenesis and therapeutic implicationsExpert Opinion on Therapeutic Targets, 2007
- A potent and orally active HIV-1 integrase inhibitorBioorganic & Medicinal Chemistry Letters, 2007
- A semiempirical free energy force field with charge‐based desolvationJournal of Computational Chemistry, 2007
- Design and synthesis of a potent macrocyclic 1,6-napthyridine anti-human cytomegalovirus (HCMV) inhibitorsBioorganic & Medicinal Chemistry Letters, 2005
- Enhancing the electron transfer capacity and subsequent color removal in bioreactors by applying thermophilic anaerobic treatment and redox mediatorsBiotechnology and Bioengineering, 2004
- Ubistatins Inhibit Proteasome-Dependent Degradation by Binding the Ubiquitin ChainScience, 2004
- UCSF Chimera—A visualization system for exploratory research and analysisJournal of Computational Chemistry, 2004
- 3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and Related 2-Urea Derivatives Are Potent and Selective Inhibitors of the FGF Receptor-1 Tyrosine KinaseJournal of Medicinal Chemistry, 2000
- Discovery of 1,6-Naphthyridines as a Novel Class of Potent and Selective Human Cytomegalovirus InhibitorsJournal of Medicinal Chemistry, 1999
- Chemical and Bioactive Constituents from Zanthoxylum simulansJournal of Natural Products, 1994